EURETINA

Today, over 150 practitioners from 20 countries in Australia, Asia and Europe enter their patient data into the Fight Retinal Blindness! Registry

Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research, networking opportunities, and empowering women in retina.

The current staging system fails to fully capture the neurovascular unit's status, said Stela Vujosevic, Md, PhD, FEBO

Discover new insights into central serous chorioretinopathy, including pathophysiology, imaging techniques, and effective treatment options for better patient outcomes.

Guymer discusses early intervention strategies for intermediate AMD, highlighting risk factors, and potential trial designs to prevent vision loss.

The ultimate goal of redefining endpoints is enabling earlier diagnosis and treatment, said Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

At the EURETINA congress, Prof Boon discussed controversies in treatment, some driven by critical prospective studies

A new staging system for diabetic retinopathy and macular edema is essential, integrating advanced imaging techniques for better disease management and patient outcomes.

The future of diabetic retinal imaging will be impacted by the use of widefield OCT-A technology, enhancing diagnosis and monitoring while addressing current limitations.

At the EURETINA congress, Prof Pollreisz shared his contemporary approach to multimodal imaging in patients with diabetes.

During the EURETINA session, Stela Vujosevic, MD, PhD, FEBO, posed questions about the current staging for diabetic macular edema and diabetic retinopathy.

Artificial intelligence is quickly expanding the breadth and depth of information clinicians can interpret, Prof Uy said

At the EURETINA meeting, Professor Uy described the ways artificial intelligence can augment an existing imaging workflow.

Timothy Lai, MD, shares promising one-year results from the SALWEEN study on faricimab for polypoidal choroidal vasculopathy at EURETINA 2025.

The EURETINA YOURS program prepares retina specialists for the EBO exam and helps them find training in the competitive subspecialty of vitreoretinal surgery.

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa.

Prof Stanzel detailed new advancements in proliferative vitreoretinopathy and a hyperaspheric IOL designed for patients with age-related macular degeneration

Prof. Querques broke down perifoveal vascular anomalous complex (PVAC) and telangiectatic capillaries (TelCaps) for congress delegates.

Prof. Androudi said differential diagnoses are more important than ever in the era of cell and gene therapies.

During her Ophthalmologica Lecture at the 2025 EURETINA Congress, Prof Cicinelli explained why it's time for a different approach to white spot syndromes.

At the 2025 EURETINA Congress, Prof Korobelnik delivered the Gisbert Richard Lecture, focusing on removal of intra-ocular foreign bodies and mitigating ocular trauma.

María Berrocal, MD, titled her Kreissig Award Lecture "Throwing away wisdom: How we abandon what works."